The Russian Direct Investment Fund (RDIF) and Gamaleya Center have announced that a first interim analysis of Phase III trials of the Sputnik V vaccine demonstrated 92% efficacy in Covid-19 patients.
Sputnik V is the first registered vaccine against Covid-19 created on a human adenoviral vector platform.
The interim data is based on the double-blind, randomised, placebo-controlled trials and is being conducted on 40,000 participants in Russia.
They analysed the efficacy among 16,000 participants who were given the vaccine or placebo 21 days after the first injection.
The analysis data on 20 confirmed Covid-19 cases showed that those who received the Sputnik V vaccine had an efficacy rate of 92% after the second dose over placebo.
In September, around 10,000 medics and other high-risk groups from the red zones of Russian hospitals were administered Sputnik V under the civil use of the vaccine out of clinical trials.
Data showed that the vaccine demonstrated an efficacy rate of over 90% in people who received the vaccine.
Over 20,000 volunteers were vaccinated with the first dose in the trials in 29 medical centres in Russia.
Participants will be observed for a period of six months, before the final report will be presented.
So far, Phase III trials are approved and are progressing in countries such as Belarus, the UAE, and Venezuela, as well as Phase II-III trials being conducted in India.
A separate study to analyse the vaccine’s safety and immunogenicity on elderly people is also progressing.
Russian Federation Health Minister Mikhail Murashko said: “The use of the vaccine and the results of clinical trials demonstrate that it is an efficient solution to stop the spread of coronavirus infection, а preventive healthcare tool, and this is the most successful path to defeat the pandemic.”
In September, the RDIF reported positive early results from the Phase I/II trials of Sputnik V.
Russia is also set to initiate post-registration trials of a second Covid-19 vaccine developed by Siberia’s Vector institute on 15 November.